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R E S E A R C HAttitudes of European Geneticists
Regarding Expanded Carrier Screening
Sandra Janssens, Davit Chokoshvili, Danya Vears, Anne De Paepe, and Pascal BorryABSTRACT
Objective: To explore attitudes of clinical and molecular geneticists about the implementation of multi-disease or
expanded carrier screening (ECS) for monogenic recessive disorders.
Design: Qualitative; semistructured interviews.
Setting: In person or via Skype. Interviews were audiorecorded and transcribed verbatim.
Participants: European clinical and molecular geneticists with expertise in carrier screening (N ¼ 16).
Methods: Inductive content analysis was used to identify common content categories in the data.
Results: Participants recognized important benefits of ECS, but they also identified major challenges, including limited
benefit of ECS for most couples in the general population, lack of knowledge on carrier screening among nongenetic
health care providers and the general public, potential negative implications of ECS for society, and limited economic
resources. Participants favored an evidence-based approach to the implementation of population-wide ECS and were
reluctant to actively offer ECS in the absence of demonstrable benefits. However, there was a consensus among the
participants that ECS should be made available to couples who request the test. In addition, they believed ECS could
be routinely offered to all people who use assisted reproduction.
Conclusion: Although a limited ECS offer is practical, it also raises concerns over equality in access to screening.
A comprehensive risk–benefit analysis is needed to determine the desirability of systematic population-wide ECS.
JOGNN, 46, 63–71; 2017. http://dx.doi.org/10.1016/j.jogn.2016.08.012
Accepted August 2016he purpose of carrier screening is to identifyT couples at risk of conceiving a child with a
monogenic recessive disorder. This risk is pre-
sent when both reproductive partners carry a
mutation associated with the same autosomal
recessive disorder or when the woman is a carrier
of an X-linked disorder (Wienke, Brown, Farmer, &
Strange, 2014).
Because of the recessive pattern of inheritance,
many carriers of these disorders have no family
history suggestive of the condition. Once identi-
fied, at-risk couples have the option to act on this
information and may alter their reproductive plans
(Ropers, 2012).
In some countries and ethnic communities with
a high birth prevalence of severe recessive
disorders, carrier screening programs were
introduced as early as the 1970s. Notable
examples of the first screening programs include
Tay-Sachs carrier screening in the Ashkenazi
Jewish community (Kaback, 2000) and premaritalª 2017 AWHONN, the Association of Women’s Health, Obstetri
Published by Elsevier Inc. All rights reserved.screening of couples for beta-thalassemia in the
Mediterranean region (Cousens, Gaff, Metcalfe, &
Delatycki, 2010). Subsequently, carrier screening
became available in some countries for condi-
tions such as cystic fibrosis (CF), fragile X
syndrome, and spinal muscular atrophy
(Metcalfe, 2012).
Because of largely technical limitations, most
tests for carrier screening have traditionally been
used to target a limited set of pathogenic muta-
tions associated with a single disorder or a small
panel of monogenic disorders (Bajaj & Gross,
2014). However, recent advances in molecular
diagnostics have resulted in the development of
expanded carrier screening (ECS) panels
capable of identifying hundreds of mutations
implicated in a large number of recessive condi-
tions (Bell et al., 2011; Kingsmore, 2012; Tanner
et al., 2014). ECS products are currently avail-
able at a price comparable to that of carrier
screening for single conditions (Higgins,
Flanagan, Von Wald, & Hansen, 2015; Langlois,c and Neonatal Nurses. 63
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Health care providers with expertise in carrier screening
are well-positioned to discuss the perceived advantages
and disadvantages of a population expanded carrier
screening program.
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64Benn, & Wilkins-Haug, 2015; McGowan, Cho, &
Sharp, 2013). The capacity to screen for more
disorders for a similar price and the ability to
identify carriers regardless of ethnicity constitute
major appeals of ECS (Cho, McGowan, Metcalfe,
& Sharp, 2013; Lazarin et al., 2012; Ready,
Haque, Srinivasan, & Marshall, 2012; Srinivasan
et al., 2010). These advantages over traditional
forms of carrier screening suggest ECS has the
potential for wide implementation in reproductive
health care (McGowan et al., 2013). Results of a
survey conducted in the United States in 2012
suggested that ECS is already routinely offered
by some obstetricians and gynecologists (Benn
et al., 2014).
Widespread adoption of ECS will profoundly
influence reproductive health care practices and
is likely to be associated with significant practical
and ethical challenges that will require special
consideration. Valuable insights can be gained
from exploring the opinions of genetic
professionals who have extensive experience
with diverse forms of genetic testing (Cho et al.,
2013). Here, we report the results of an
interview-based study with European clinical and
molecular geneticists and present the issues that
surround the implementation of ECS in repro-
ductive medicine.Methods
Because of the explorative nature of our research
question, we conducted key informant interviews
with clinical and molecular geneticists to investi-
gate their views about the implementation of ECS
in reproductive health care (Popay, Rogers, &
Williams, 1998). Participants were eligible for
inclusion if they were practicing clinical or
molecular geneticists based in the European
Economic Area and had demonstrable expert
knowledge in carrier screening, such as author-
ship of relevant scientific publications or confer-
ence abstracts. Potential participants were
identified by members of our research team
and invited to participate via e-mail. Additional
respondents were recruited by snowball sam-
pling, where we asked our participants to identify
colleagues with expertise in carrier screening.JOGNN, 46, 63–71; 2017. http://dx.doi.org/10.1016/j.jogn.2016.0Interviews were conducted using a semi-
structured interview guide, which allowed for
in-depth exploration of issues related to imple-
mentation of ECS (Liamputtong & Ezzy, 2005).
Interviews took place between April and
September 2014 and were audiorecorded
and transcribed verbatim to enable coding and
analysis.
Inductive content analysis was used to identify
common content categories from the interviews,
rather than coding using a predetermined coding
scheme (Downe-Wamboldt, 1992; Graneheim &
Lundman, 2004; Schamber, 2000). The data
were coded into broad categories before
sections of the data within these categories were
compared and more specific content categories
were developed. Coding was performed by DC
using the qualitative data management software
QSR Nvivo; data were reviewed by all members
of the research team for validation. This study was
approved by the institutional ethics committee of
the University Hospital Ghent.Results
The group of participants included 16 genetics
professionals from eight member states of the
European Economic Area. The group included
13 clinical geneticists (CGs), 2 molecular genet-
icists (MGs), and 1 medical geneticist with
expertise in clinical and molecular genetics
(CMG). At the time of the interviews, all partici-
pants were affiliated with an academic institution,
and 12 geneticists (9 CGs, 2 MGs, 1 CMG) had
more than 20 years of professional experience in
clinical or diagnostic practice. Eleven partici-
pants were female, and five were male.
Thirteen interviews took place in person, and
three were conducted via Skype. Three cate-
gories relevant to the implementation of large-
scale ECS programs were identified from the
data: Potential benefits of ECS, Challenges of
population-wide carrier screening using
expanded panels, and Models for provision of
ECS. These categories and their subcategories
are described below and are accompanied by
illustrative quotes from the participants.Category 1: Potential Benefits of ECS
All participants believed that systematically
offering preconception ECS to prospective par-
ents would result in significant potential benefits,
such as reduced cost of ECS and greater access
to testing. Overall, there was agreement that8.012 http://jognn.org
Janssens, S., Chokoshvili, D., Vears, D., De Paepe, A., and Borry, P. R E S E A R C Hprovision of ECS to the general population was
desirable because currently many at-risk couples
have no possibility of learning about their repro-
ductive risks. For example, one participant com-
mented, “At the moment, we have a situation
where most people with most conditions only
have the possibility of making informed decisions
about reproduction when they already have an
affected child and that is . not good” (CG).
Furthermore, several participants highlighted the
ability of ECS to identify carriers in the general
population, regardless of ethnicity. For some
participants, this meant that ethnicity-based
testing would soon fall out of favor, a develop-
ment they welcomed:
People don’t want to have themselves
registered in a hospital based on [their]
ethnicity. If you make one panel, and. the
technique is progressing and it’s becoming
more and more easy to put a lot of muta-
tions on one panel for a relatively low price.
I think you should put it all on one panel to
prevent discrimination issues. (CG)
Category 2: Challenges of Population
Carrier Screening Using Expanded
Panels
Despite the potential benefits of ECS, participants
identified several major challenges associated
with systematic implementation of ECS.
Subcategory 2.1: Limited utility of ECS for the
general population. Some participants noted that
the yield of carrier couples from population-wide
ECS would be low. This was partly attributed to
the inability of current ECS products to identify
many carrier couples because ECS panels would
not include all disease-associated mutations.
According to participants, the incomplete
coverage of pathogenic mutations would make it
impossible to completely exclude the risk of
having an affected child. Consequently, several
participants were particularly concerned that
many couples in which only one partner is iden-
tified as a carrier would experience excessive
anxiety over this residual risk:
[I have seen a couple where the husband]
had a family history of cystic fibrosis and
he was screened positive for the most
frequent mutations and then we screened
the wife [and] she was screened negative.
But it was a rare mutation and they expe-
rienced the disease. If you screen for manyJOGNN 2017; Vol. 46, Issue 1diseases, you will find many [couples
where] one member of the couple will be a
carrier and for the other one you won’t be
able to lower the risk enough to reassure
completely them. So I think this gap is
problematic for [couples] because many
will be anxious and not much will be really
reassured, and very few will be really
at risk. (CG)
In the case of multidisease panels, several par-
ticipants believed that because both members of
a couple may carry novel or private mutations in
genes associated with recessive disorders, the
couple’s residual risk of having an affected child
would be quite high. The probability of identifying
couples with confirmed high risk, on the
other hand, was perceived to be low (estimated
at 1%–3% by several participants). Because of
this, participants believed that population-wide
ECS would benefit only a small minority of
participating couples and that for the remainder
of couples, testing would be an unnecessary
intervention that could potentially lead to psy-
chological distress: “All this testing, anxiousness,
maybe finding something which you don’t know
what the meaning is. [this] is stirring up every-
thing and for most people it’s not relevant, but we
do it for those few couples” (CG).
Similarly, another participant discussed the
absence of any immediate medical benefit for
most couples and referred to the possibility of
experiencing undue anxiety as the “collateral
damage” (CMG) of population-wide ECS.
Subcategory 2.2: Lack of public education on
carrier screening. To promote informed decision
making about screening, participants believed it
would be necessary to ensure that all prospective
parents undergoing ECS understood the aims
and implications of the test. However, all partici-
pants expressed doubt regarding the general
public’s ability to comprehend issues surrounding
preconception carrier screening. In particular,
they were concerned that prospective parents
may have difficulty understanding the meaning of
being a carrier: “I think for the general public[’s]
understanding of what it means to be a carrier it is
perhaps not yet good enough to be able to
distinguish between carrier and affected status”
(CG).
Most participants believed the poor genetic liter-
acy among the lay public would pose significant
challenges to large-scale implementation of ECS.65
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mentation of population-wide ECS should be
preceded by public education efforts to ensure
“that people would understand the issue. Would
understand what is at stake, including the
uncertainty there is” (CMG).
Subcategory 2.3: Lack of genetic education and
counseling expertise among health care provi-
ders. All participants believed a successful
population-wide carrier screening program would
require active involvement of nongenetic health
care professionals to inform and educate pro-
spective parents about ECS. However, some
participants were concerned that health care
providers often lack sufficient genetic knowledge
to be able to provide adequate counseling:
“I think at the moment many colleagues are not
capable to counsel people about genetics. It’s
completely out of their understanding, I would
say” (CG). Consequently, participants empha-
sized the importance of educated counselors and
stressed that ECS should not be offered to the
general population without taking preparatory
measures.
If you test for a lot of disorders, then the
probability you find that carrier couple is
there. So you must be very prepared, know
these disorders; you have to be able to
explain that very well. This [ECS] could
be very interesting, but we need time to
plan this kind of stuff. To educate our-
selves, to make good counseling, and [to
devise good practice guidelines]. (MG)
Subcategory 2.4: Possible negative societal
implications of ECS. Some participants argued
that offering ECS to the general public would
result in a lower birth prevalence of children
affected with recessive disorders: “If we imagine
that there will be systematic carrier screening in
the population, probably the disease[s] will really
decrease and most of those patients will never be
born” (MG). One participant articulated concerns
that a widespread offer of ECS would result in
discontent among some members of the general
public: “[Some people fear that] we [geneticists]
want to make a perfect population, so then there
will be no chance for these children to [be
born]. I mean, these extreme groups always see
this as some form of eugenics” (CG). Another
participant believed that implementation of ECS
could be particularly controversial for people
currently living with the disorders: “[T]hose peo-
ple with the disease will feel, well, not at ease orJOGNN, 46, 63–71; 2017. http://dx.doi.org/10.1016/j.jogn.2016.0embarrassed with it, saying that ‘What is the
legitimacy if you now avoid the birth of additional
people with conditions we have?’” (CMG).
Recognizing the possible controversy of ECS
among people with recessive diseases, partici-
pants called for more extensive discussion on the
far-reaching societal effects of ECS: “So a part of
the whole discussion would need to be about
what it would be about to live in a society that had
very few cases of . most recessive conditions.
Would that be a good thing or not?” (CG).
Category 3: Proposed Models for
Providing ECS
Participants discussed the following possible
models for large-scale implementation of ECS:
systematically offering screening to all
reproductive-age couples, providing ECS upon
request from prospective parents, and incorpo-
rating ECS into artificial reproduction services for
people who undergo fertility treatment.
Subcategory 3.1: Systematic screening of all
reproductive-age couples. Most participants
believed that ideally, ECS would be implemented
in such a way that ensures equal access to carrier
screening for all prospective parents: “It will be
important to make sure that all sections of society
have ready access to it. So it would be bad if only
the wealthy had access to it. Sure, it needs to be
available generally” (CG). Some believed the
significant improvement in technology of ECS
compared with carrier screening for single con-
ditions provides a rationale for considering the
implementation of a systematic population
screening program:
In the older days, I might have said, “No,
it’s not worth the investment and the
technology and the time to test for individ-
ual rare conditions.” [Now] if you’re talking
about expanded carrier testing, the whole
equation becomes very different from what
it used to [be]. (CG)
However, this participant also noted it is unclear
whether ECS has reached the stage at which the
overall benefits of implementation outweigh the
potential disadvantages, and a comprehensive
analysis of benefits and harms was recom-
mended “in order to decide whether you would
justify offering it to a general population.”
In addition, one participant stated that the public
health care system in his/her country was8.012 http://jognn.org
Most participants believed it was premature to implement
expanded carrier screening in the context of public health.
Janssens, S., Chokoshvili, D., Vears, D., De Paepe, A., and Borry, P. R E S E A R C Hoperating on a limited budget. Therefore, the
health care system could not prioritize ECS, a
screening program likely to benefit only a small
part of the population, because of the presence
of more pressing health care needs:
Here, it’s not the best we can do with the
amount of resources we have. I do feel
that it causes a huge amount of anxiety in
families if they have a kid with recessive
disorder, although economically it’s waste
of time. So you spend huge, huge
amount of money and you are probably
better off [treating] Alzheimer’s patients or
your cancer patients. (CG; emphasis by
interviewee)
Subcategory 3.2: Providing ECS upon request.
There was a general consensus among partici-
pants that ECS should be made available to
couples willing to take the test to enhance their
reproductive autonomy: “When you think of the
autonomy of the prospective parents, the offer
should be there” (CG). Notably, willingness to
provide carrier screening upon request was also
expressed by those participants who believed
that actively offering ECS to the general
population was premature at present: “[Taking
into consideration the disadvantages], I am not
sure I would today use carrier screening for
many conditions simultaneously, except if
people really want them” (CG; emphasis by
interviewee).
However, some respondents believed that unless
the overall benefits of ECS are shown to outweigh
the potential harms, prospective parents should
be responsible for the cost of the test:
I do think that something like that at the
moment must be paid by the patient. If I
decide, because I’m very anxious, to get
this kind of tests and see if I’m a carrier of
one of those disorders, I have to pay. Not
the insurance, not the government. It’s
right to have a possibility to do that but also
the people should pay for that. (MG)
Subcategory 3.3: ECS in the context of artificial
reproductive technologies. Despite acknowl-
edging the considerable challenges associated
with population-wide ECS, participants agreed
that it was justifiable to systematically provide
ECS to high-risk groups of prospective parents,
such as consanguineous couples or individuals
with family histories of a recessive disorder. InJOGNN 2017; Vol. 46, Issue 1addition, several participants believed ECS could
be successfully integrated into preimplantation
genetic diagnosis (PGD) services, with substan-
tial benefits.
I want to stress especially from the point of
couples asking for PGD, I’m in favor of
preconception carrier screening. Because
they [patients] already have one genetic
problem and you don’t want them to be
confronted with another genetic problem
and [have to tell them] in retrospect, “We
did have a possibility to identify this prob-
lem, but we didn’t offer it to you.” I think
that’s not good. (CG)
Let’s say I see a couple and they have a
child with a metabolic condition, recessive,
and I offer them [ECS]. So it’s easy to say,
“[these are] disease[s] like your child’s, you
both have to be carriers, and so on.”
It takes less time to explain. (CG)
In addition, one participant argued that ECS could
be routinely provided to all people undergoing
in vitro fertilization treatments in general. This
participant emphasized the duty of medical pro-
fessionals to protect children conceived through
medical procedures from preventable harm:
Both of the procedures [in vitro fertilization
and PGD] are basically medical proced-
ures, firstly for the couple to have a baby at
all or a couple with a genetic problem not to
have this genetic problem. So in this situ-
ation, any additional genetic disorder
[resulting from] this medical treatment
would be somehow iatrogenic failure of the
medical procedure. (CG)
Discussion
We investigated the attitudes of European clinical
and molecular geneticists toward the imple-
mentation of population-wide ECS. All partici-
pants recognized the potential benefits of ECS,
including the identification of at-risk couples
without a preexisting risk for a genetic disorder
and subsequently increasing their reproductive
autonomy. Furthermore, the ability to incorporate
additional disorders for little extra cost into ECS
panels was viewed as a significant improvement67
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ever, participants also identified several major
challenges to large-scale implementation of ECS.
Our participants noted that, in their current form,
ECS tests fail to identify many carriers in the
general population because the panels do not
include extremely rare or novel pathogenic
mutations. This inability to completely exclude the
possibility that an individual with a negative
screening result could be a carrier was also
highlighted as a major limitation of ECS by
genetics professionals in a U.S.-based focus
group study (Cho et al., 2013). Our participants
accepted non-negligible risk of missing carriers to
maximize positive predictive value of the test.
They recommended limiting ECS to highly pene-
trant pathogenic mutations with clearly estab-
lished genotype–phenotype correlations, even if
this would result in a decreased sensitivity
(unpublished data).
However, our participants raised concerns that
the residual risk of having an affected child after a
negative test result would lead to undue anxiety in
couples where only one partner is found to carry
a disease-associated variant in the gene (also
referred to as þ/ couples; Henneman & ten
Kate, 2002). Because individuals in the general
population are estimated to carry several patho-
genic mutations associated with severe mono-
genic disorders (Bell et al., 2011), it is reasonable
to expect that any ECS test would identify a large
proportion of couples as þ/ for at least one
disorder. Imperfect carrier detection rates for
disorders using ECS panels have been reported
previously, with authors warning that inconclusive
test results could prompt some þ/ couples to
undergo extensive and costly follow-up genetic
evaluation, often with little benefit (Skirton, 2015;
Stoll & Resta, 2013). Because the proportion of
carrier couples in the general population is low
and population-based ECS tests using mutation
panels would identify couples even less at risk,
only a small proportion of screened couples
would receive actionable findings (Bajaj & Gross,
2014; Stoll & Resta, 2013).
For most couples, as emphasized by our partic-
ipants, ECS would be of no medical benefit,
would constitute an unnecessary, potentially
burdensome medical intervention, and may lead
to emotional distress because of inconclusive test
results. These potential negative outcomes of
ECS need to be factored in when assessing the
desirability of ECS.JOGNN, 46, 63–71; 2017. http://dx.doi.org/10.1016/j.jogn.2016.0Given the many complex issues related to ECS,
our participants viewed it as essential to ensure
that all prospective parents who undergo
screening possess adequate knowledge of the
implications and limitations of the test. This is in
line with recent recommendations from profes-
sional organizations that have encouraged pro-
viders of ECS to focus pretest education and
consent processes on explaining these issues,
including the meaning of being a carrier, the
pattern of inheritance, and the technical limita-
tions of the tests (Edwards et al., 2015;
Henneman et al., 2016). These recommenda-
tions are aimed at facilitating informed decision
making for potential parents, yet the effective-
ness of this approach will greatly depend on the
couple’s genetic literacy. Participants in our study
questioned the capacity of the general popula-
tion to comprehend the complex issues sur-
rounding ECS and viewed this as an important
barrier to the successful provision of population
ECS.
To ensure the understandability of the information
related to carrier screening, it may be necessary
to improve the general public’s knowledge of
genetics (Health Council of The Netherlands,
1994). Furthermore, our participants were con-
cerned that many health care professionals lack
the necessary expertise to inform and counsel
their patients on various aspects of ECS, as
advanced by genetics professionals in another
study (Cho et al., 2013). Lack of expertise about
carrier screening among nongeneticist health
care providers poses an important challenge,
because their competence and cooperation will
be crucial for successful implementation of
screening programs (Bailey, Lewis, Roche, &
Powell, 2014; Metcalfe, 2012). Moreover, as the
information on ECS becomes more widely
accessible, nongeneticist health care providers,
such as general practitioners, are likely to be
confronted with enquiries related to carrier
screening from their patients (Poppelaars et al.,
2003). It is therefore critical to ensure that health
care providers possess sufficient knowledge to
discuss carrier screening with their patients.
Some participants anticipated that ECS would
result in a lower prevalence of recessive disor-
ders in the population. Their expectation is sup-
ported by historical data on population-wide
cystic fibrosis carrier screening, which suggests
that an offer of carrier screening does lead to
reductions in the number of affected births over
time (Castellani et al., 2015). In line with the8.012 http://jognn.org
Janssens, S., Chokoshvili, D., Vears, D., De Paepe, A., and Borry, P. R E S E A R C Hconcerns raised by our participants, consider-
able attention in the literature has been devoted
to ethical issues such as perceived eugenic
undertones of carrier screening and negative
implications for people with the screened disor-
ders (Bruni, Mameli, Pravettoni, & Boniolo, 2012;
De Wert, Dondorp, & Knoppers, 2012). It is
important to acknowledge the significance of
these concerns and take preemptive measures to
mitigate the potential harm of widespread ECS.
First, population carrier screening offers must be
voluntary, where informed couples can exercise
their reproductive autonomy and feel free to
decline participation (G. M. De Wert et al., 2012).
Second, people with disabling monogenic
conditions must continue to receive adequate
medical care and suffer no foreseeable discrimi-
nation as a result of the program (Henneman
et al., 2016; Raz, 2005). Contrary to the beliefs
expressed by some of our participants, authors of
studies with people with recessive disorders and
their family members have reported positive
attitudes toward population carrier screening
(Henneman et al., 2001; Hietala et al., 1995;
Janssens et al., 2015). However, views on
carrier screening can vary substantially across
cultures, and societal issues surrounding ECS
should be discussed with different stakeholders
from the general public, including people with
recessive disorders (Mosconi, Castellani, Villani,
& Satolli, 2014).
Because of significant challenges and concerns
associated with population ECS, some partici-
pants suggested that any plans for routine inte-
gration of ECS into medical services should be
preceded by a careful analysis of anticipated
benefits and risks. These participants favored an
evidence-based approach to ECS and were
reluctant to accept its implementation in the
absence of demonstrated overall benefit.
However, such an evaluation is challenging and
may require carrying out pilot studies (Wilfond &
Goddard, 2015). Furthermore, because carrier
screening programs should emphasize voluntary
participation and avoid a focus on increasing
uptake (Poppelaars et al., 2003), a population-
wide carrier screening program cannot aim to
achieve a targeted participation rate. Conse-
quently, it may be unclear to policymakers
whether spending public resources on ECS is
justified, particularly in light of other public health
interventions competing for the same pool of
resources. Therefore, as several participants in
our study noted, some countries may not be in a
position to prioritize ECSbecause of the presenceJOGNN 2017; Vol. 46, Issue 1of more pressing public health issues and limited
available resources.
Although most participants believed that sys-
tematically offering ECS to all couples in the
general population was associated with signifi-
cant challenges, there was a general consensus
that ECS should be made available to prospec-
tive parents who request it. This observation is in
line with findings of other attitudinal studies,
where health care professionals were more sup-
portive of carrier screening if their patients
requested the test (Baars, Henneman, & ten Kate,
2004; Benn et al., 2014). In addition, some par-
ticipants believed ECS could be routinely offered
to select groups of prospective parents, such as
those who pursue pregnancy through artificial
reproductive technologies, which mirrors the
findings of others (Cho et al., 2013). Routine
provision of ECS in the context of artificial repro-
duction has been gaining support because of
professional obligations to avoid harm to future
children (G. De Wert et al., 2011) and the relative
ease and low incremental cost of integrating ECS
into extant fertility services (Bell et al., 2011; Cho
et al., 2013; Kingsmore, 2012).
An important disadvantage of a limited offer of
ECS is that initially not all members of the general
public would be aware of its existence (Baars
et al., 2004). Furthermore, assuming a fee-for-
service model of provision, it is likely that some
prospective parents interested in ECS will not be
able to afford the service, which raises concerns
over equity in access to screening. Additionally,
geneticists and reproductive health care pro-
viders in other studies have raised concerns that
failure to offer carrier screening may result in
lawsuits in some jurisdictions, should a child with
a detectable disorder be born (McGowan et al.,
2013; Stark et al., 2013). These concerns indi-
cate that there would be advantages to system-
atically offering carrier screening to all couples of
reproductive age. To this end, it is important that
in the near future a comprehensive risk–benefit
analysis of ECS is carried out, assessing the
expected medical, psychosocial, and economic
impact of ECS. Should such analyses show an
overall benefit of ECS, the practice could be
introduced as a standard of care, resulting in an
equitable offer of population carrier screening
(Ferreira et al., 2014).
Strengths and Limitations
Because the literature on ECS is still sparse, our
study provides a valuable contribution by69
A comprehensive risk–benefit analysis of expanded carrier
screening that incorporates economic and psychosocial
implications is required.
Expanded Carrier ScreeningR E S E A R C H
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the implementation of this emerging technology.
To this end, the principal strength of our study is
that we interviewed genetic professionals with
expertise in carrier screening for recessive dis-
orders who, arguably, are the most qualified
stakeholders to discuss these issues. However, it
should be noted that the vast majority of our
participants were affiliated with established
health care institutions, such as hospitals,
academic medical centers, and other publicly
funded bodies. Consequently, our participants
largely discussed ECS in the context of public
health, which may explain their adoption of
a cautious, evidence-based approach to the
implementation of ECS. Studies with other
stakeholders are required to gain a deeper and
more comprehensive insight into the benefits and
disadvantages of the implementation of ECS.Conclusion
Although our participants had positive attitudes to-
ward ECS, they also identified several major chal-
lenges to a population-wide offer of carrier screening
and were reluctant to accept systematic ECS in the
absence of demonstrated overall benefit. This obser-
vation indicates a strong need for a comprehensive
risk–benefit analysis of ECS, factoring in expected
medical, psychosocial, and economic impacts.
Regardless of the desirability of a systematic ECS
offer to all couples considering pregnancy, our
participants believed that ECS should be made
available to those couples who request the test. In
addition, therewas a consensus that ECS could be
routinely offered to all people who receive assisted
reproduction services, such as PGD and, more
generally, in vitro fertilization. Although limited
availability of ECS offers benefits to some pro-
spective parents, it also raises concerns over eq-
uity in access. Therefore, assuming feasibility and
desirability of ECS, efforts will need to focus on
making screening accessible to all couples of
reproductive age in the general population.Acknowledgment
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